The drug candidate, depemokimab, was measured in severe asthma patients with Type 2 inflammation characterized by blood eosinophil count, GSK said in a May 21 news release. Compared to a placebo, study participants who took depemokimab experienced fewer asthma attacks over 52 weeks.
The biologic is designed to be administered twice a year, and it’s the first ultra-long-acting severe asthma treatment to be tested in a phase 3 trial, the release said. GSK said it plans to share more data at an upcoming conference and file for regulatory approval.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
